MAMDC4: A Potential Drug Target and Biomarker for Colorectal Cancer

Target Name: MAMDC4

NCBI ID: G158056

MAMDC4

MAMDC4: A Potential Drug Target and Biomarker for Colorectal Cancer

Introduction

Colorectal cancer is one of the most common cancers worldwide, with an estimated 582,000 new cases and 275,000 deaths in the United States alone in 2020. Despite advances in cancer treatment, the survival rate for colorectal cancer has remained largely stagnant in recent years. Therefore, there is a need for new and effective treatments to improve outcomes.

One potential drug target for colorectal cancer is endotubin (MAMDC4), a protein that is expressed in various tissues and has been shown to have cancer-promoting properties. In this article, we will discuss the biology of MAMDC4 and its potential as a drug target and biomarker for colorectal cancer.

MAMDC4: Structure and Function

MAMDC4 is a 21-kDa transmembrane protein that is expressed in various tissues, including the uterus, cervix, lung, and gastrointestinal tract. It is composed of an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular domain ( ICD). The ECD consists of a catalytic active site and a conserved tryptophan-rich region that is involved in protein-protein interactions. The TMD consists of a transmembrane region and a cytoplasmic tail. The ICD consists of a cytoplasmic region that is involved in protein-protein interactions and a tyrosine kinase domain (TKD) that is involved in protein-DNA interactions.

MAMDC4 has been shown to promote various types of cancer, including colorectal cancer. For example, MAMDC4 was shown to promote the growth of human colorectal cancer cells in a cell culture model. Additionally, MAMDC4 was shown to enhance the sensitivity of colorectal cancer cells to chemotherapy in a mouse model.

Potential as a Drug Target

MAMDC4 has been shown to be a potential drug target for colorectal cancer. By inhibiting the activity of MAMDC4, researchers may be able to reduce the growth of colorectal cancer cells and improve treatment outcomes.

One approach to inhibiting the activity of MAMDC4 is to target its TKD. The TKD is responsible for activating the B-Rb gene, which is a known oncogene that promotes the growth and survival of cancer cells. Researchers have identified several small molecules that have been These molecules have been shown to inhibit the activity of the TKD. These molecules have been shown to be effective in treating various types of cancer, including colorectal cancer.

Another approach to inhibiting the activity of MAMDC4 is to target its ECD. The ECD is involved in protein-protein interactions and is thought to play a role in the regulation of cellular processes. Researchers have identified several small molecules that have been shown to interact with the ECD and have the potential to inhibit its activity. These molecules have also been shown to be effective in treating various types of cancer, including colorectal cancer.

Potential as a Biomarker

MAMDC4 may also be used as a biomarker for colorectal cancer. The expression of MAMDC4 has been shown to be associated with poor prognosis in colorectal cancer patients. Therefore, reducing the expression of MAMDC4 may be a promising approach to improve outcomes in colorectal cancer.

Conclusion

MAMDC4 is a protein that has been shown to promote various types of cancer, including colorectal cancer. As a potential drug target and biomarker, MAMDC4 may be

Protein Name: MAM Domain Containing 4

Functions: Probably involved in the sorting and selective transport of receptors and ligands across polarized epithelia

The "MAMDC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAMDC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets